Actuate Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Actuate Therapeutics

12/08/2026 21:16

Actuate Therapeutics Inc ACTU.OQ ACTU.O is expected to  show no change in quarterly revenue when it reports  results on August 14 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Actuate Therapeutics Inc is for a loss of 19 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Actuate Therapeutics Inc is $13.50, about 1,236.6% above its last closing price of $1.01
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.22
-0.22
-0.24
Missed
-10.8
Dec. 31 2026
-0.24
-0.24
-0.18
Beat
26.5
Sep. 30 2025
-0.28
-0.28
-0.25
Beat
9.9​
Jun. 30 2025
-0.32
-0.31
-0.31
Met
1.6
​​Mar. 31 2025
-0.30
-0.30
-0.32
Missed
-5.5
Dec. 31 2024
-0.29
-0.29
-0.33
Missed
-13.8​
This summary was machine generated August 12 at 20:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)